AbbVie (ABBV) said Thursday that atogepant for the preventive treatment of menstrual migraine in adults met its primary and all eight ranked secondary endpoints in the Phase 3 LUNA study.

Atogepant demonstrated a greater reduction than placebo in migraine days during the perimenstrual period, with an average reduction of 1.20 migraine days with atogepant versus 0.40 days with placebo, according to the company.

Additionally, the therapy showed "statistically significant and clinically meaningful" improvements versus placebo across all eight ranked secondary endpoints, including measures of headache burden, acute medication use, functional disability, cognitive function and responder outcomes, AbbVie said.

Atogepant is marketed as AQUIPTA in the EU and as QULIPTA in the US, Canada, Israel and Puerto Rico, according to a statement.